Yuval Cohen sold $471k of CRBP
Chief Executive Officer at Corbus Pharmaceuticals Holdings, Inc.. 27,633 shares at an average of $17.05, traded Oct 24, 2025, filed Oct 27, 2025.
Score components
- +25RoleCEO
- +17Trade size$471k at market
- +5Share of holdings soldSold 18% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -30.2%, 3m -45.1%, 6m -40.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-251639, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 24, 2025 | MOption exercise Common Stock, par value $0.0001 per share10b5-1 | +18,660 | $4.26 | $79k | 156,847 | Oct 27, 2025 |
| Oct 24, 2025 | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -18,660 | $17.01 | $317k | 138,187 | Oct 27, 2025 |
| Oct 27, 2025 | MOption exercise Common Stock, par value $0.0001 per share10b5-1 | +8,973 | $4.26 | $38k | 147,160 | Oct 27, 2025 |
| Oct 27, 2025 | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -8,973 | $17.14 | $154k | 138,187 | Oct 27, 2025 |
| Oct 24, 2025 | MOption exercise Stock options (right to buy)derivative10b5-1 | -18,660 | $0.00 | $0 | 31,079 | Oct 27, 2025 |
| Oct 27, 2025 | MOption exercise Stock options (right to buy)derivative10b5-1 | -8,973 | $0.00 | $0 | 22,106 | Oct 27, 2025 |
Related signals
Other insiders at Corbus Pharmaceuticals Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Corbus Pharmaceuticals Holdings, Inc. | Yong Ben director | $16k 2,000 shares | -18% | |
| 33Weak | CRBPbuy Corbus Pharmaceuticals Holdings, Inc. | Nishant C Saxena Chief Business Officer | $25k 2,600 shares | +3% | |
| 24Weak | Corbus Pharmaceuticals Holdings, Inc. | Yuval Cohen Chief Executive Officer | $171k 17,000 shares | -10% | |
| 25Weak | Corbus Pharmaceuticals Holdings, Inc. | Sean F. Moran Chief Financial Officer | $121k 12,000 shares | -12% | |
| 15Weak | Corbus Pharmaceuticals Holdings, Inc. | Anne Altmeyer director | $19k 2,412 shares | -24% | |
| 36Weak | Corbus Pharmaceuticals Holdings, Inc. | John Kenneth Jenkins director | $38k 4,800 shares | -56% | |
| 15Weak | Corbus Pharmaceuticals Holdings, Inc. | Winston Kung director | $16k 2,026 shares | -14% | |
| 49Moderate | CRBPbuy Corbus Pharmaceuticals Holdings, Inc. | Nishant C Saxena Chief Business Officer | $101k 13,500 shares | +22% | |
| 30Weak | Corbus Pharmaceuticals Holdings, Inc. | Dominic Smethurst Chief Medical Officer | $51k 6,097 shares | -6% | |
| 30Weak | Corbus Pharmaceuticals Holdings, Inc. | Yuval Cohen Chief Executive Officer | $108k 13,871 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.